
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: 1 Department of Clinical and Biological Sciences, School of Medicine, University of Insubria, Varese, Italy; 2 Laboratory of Cellular Biology and 3 Laboratory of Immunological Therapy, Istituto Nazionale per la Ricerca sul Cancro; 4 Laboratory of Experimental and Clinical Immunology, Istituto G. Gaslini; and 5 Unit of Innovative Therapy, Advanced Biotechnology Center, Genova, Italy
Requests for reprints: Roberto S. Accolla, Department of Clinical and Biological Sciences, School of Medicine, University of Insubria, Via Ottorino Rossi, 9, 21100 Varese, Italy: Phone: 39-348-3034698; Fax: 39-0332-217219; E-mail: roberto.accolla{at}uninsubria.it.
Purpose: We have shown previously that the MHC class IInegative murine TS/A adenocarcinoma is rejected in vivo if induced to express MHC class II molecules by transfection of the MHC class II transactivator CIITA. In this study, we explored the immunologic basis of tumor rejection and the correlation between histopathology of tumor tissue and immune rejection.
Experimental Design: Stable TS/A-CIITA transfectants were generated and injected into mice. In vivo cell depletion, immunohistochemistry of tumor tissues, and immune functional assays were done to assess the cellular and immunologic basis of rejection.
Results: Ninety-two percent of mice injected with TS/A-CIITA rejected the tumor and were completely resistant to challenge with parental TS/A. Only CD4+ and CD8+ cells were required for rejection. The tumor microenvironment in TS/A-CIITA-injected mice changed dramatically when compared with the TS/A parental-injected mice. Rapid infiltration with CD4+ T cells followed by dendritic cells, CD8+ T cells, and granulocytes was observed. Importantly, TS/A-CIITA cells could act as antigen-presenting cells because they process and present nominal antigens to CD4+ T cells. Tumor-specific CD4+ T cells of TS/A-CIITA-injected mice had the functional characteristics of Th1 cells and produced IFN-
and this was relevant for generation and maintenance of protective antitumor response, because IFN-
knockout mice were no longer rejecting TS/A-CIITA tumor cells.
Conclusion: CIITA-dependent MHC class II expression confers to TS/A tumor cells the capacity to act as a protective vaccine against the tumor by triggering tumor antigen presentation to T helper cells, antitumor polarization of cellular and soluble components of the tumor microenvironment, and establishment of antitumor immune memory.
This article has been cited by other articles:
![]() |
L. Mortara, V. Frangione, P. Castellani, A. De Lerma Barbaro, and R. S. Accolla Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions Int. Immunol., June 1, 2009; 21(6): 655 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. De Lerma Barbaro, A. De Ambrosis, B. Banelli, G. L. Pira, O. Aresu, M. Romani, S. Ferrini, and R. S. Accolla Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-{gamma} in promyelocytic cells Int. Immunol., November 1, 2008; 20(11): 1457 - 1466. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. de Bruin, C. J.H. van de Velde, J. H. J.M. van Krieken, C. A.M. Marijnen, and J. P. Medema Epithelial Human Leukocyte Antigen-DR Expression Predicts Reduced Recurrence Rates and Prolonged Survival in Rectal Cancer Patients Clin. Cancer Res., February 15, 2008; 14(4): 1073 - 1079. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |